Market Closed - Nyse 04:00:02 2024-12-09 pm EST 5-day change 1st Jan Change
44.32 USD +2.07% Intraday chart for Qiagen N.V. +1.53% -1.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Qiagen Reports Over 1,000 Placements of EZ2 Connect Instrument Globally Dec. 05 MT
Qiagen N.V. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-05-2024 10:50 AM Dec. 05
Qiagen Seeks Bolt-On Acquisitions Dec. 04 CI
Qiagen N.V. Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 02:30 PM Dec. 04
Qiagen Plans to Open New Facility in Spain in 2026 Nov. 29 MT
QIAGEN Launches Novel Tools for Customizing Digital PCR Assays and NGS Panels for Microbial Analysis Nov. 27 CI
Qiagen N.V. Presents at 6th Annual Wolfe Research Healthcare Conference 2024, Nov-20-2024 12:40 PM Nov. 20
QIAGEN NV : Jefferies is Neutral Nov. 20 ZD
Qiagen N.V. Presents at Jefferies London Healthcare Conference 2024, Nov-20-2024 09:00 AM Nov. 20
Qiagen N.V. Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 09:00 AM Nov. 19
Qiagen Partners With McGill University for Microbiome Research Nov. 13 MT
Qiagen, McGill University Enter Partnership Deal for Microbiome Research Development Nov. 13 MT
Qiagen Collaborates with McGill University to Advance Microbiome Research Nov. 12 CI
QIAGEN NV : UBS reiterates its Neutral rating Nov. 11 ZD
Qiagen N.V., Q3 2024 Earnings Call, Nov 07, 2024 Nov. 07
QIAGEN NV : Deutsche Bank reaffirms its Buy rating Nov. 07 ZD
QIAGEN : Markets hailed the Q3 beat + the profitability upgrade Nov. 07Alphavalue
QIAGEN NV : Receives a Buy rating from Berenberg Nov. 07 ZD
Qiagen Q3 Adjusted Earnings, Revenue Increase; Raises 2024 Adjusted Earnings Guidance Nov. 07 MT
QIAGEN NV : UBS reaffirms its Neutral rating Nov. 07 ZD
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 06 CI
Diagnostics firm Qiagen reports rise in third-quarter revenue Nov. 06 RE
Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024 Nov. 06 CI
QIAGEN Says FDA Cleared QIAstat-Dx Panel for Meningitis/Encephalitis Nov. 04 MT
Qiagen Secures US FDA Nod for Meningitis, Encephalitis Panel Nov. 04 MT
Chart Qiagen N.V.
QGEN: Dynamic Chart
Logo Qiagen N.V.
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Employees
5,800
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
surperformance-ratings-light-chart QIAGEN-N-VMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
44.32USD
Average target price
51.26USD
Spread / Average Target
+15.66%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. News Qiagen N.V.
  5. Qiagen Q3 Adjusted Earnings, Revenue Increase; Raises 2024 Adjusted Earnings Guidance